P‐TS‐76 | Safety and Efficacy of Amotosalen‐UVA Pathogen Reduced Platelet Components Transfused to Mature and Premature Neonates
Laurence Corash(Cerus (United States)), Behrouz Mansouri Taleghani(University of Bern), Johannes Irsch(Cerus (United States)), Michael Daskalakis(University of Bern), Jane McDougall(University Hospital of Bern), L. Hyseni(University Hospital of Bern)
Cited by 0
Related Papers
Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion
|Archives of Gynecology and Obstetrics|2019|96
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia
|The American Journal of Medicine|2003|72
Familial Clustering of High Factor VIII Levels in Patients With Venous Thromboembolism
|Arteriosclerosis Thrombosis and Vascular Biology|2001|70
Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.
|PubMed|2004|66
Oxaliplatin‐induced immune pancytopenia
|Transfusion|2005|65